feedback

Course Director

Professor Florence Cymbalista, MD, PhD
Professor Florence Cymbalista, MD, PhD

Hopital Avicenne, AP-HP
University of Paris 13
Bobigny, France

Faculty

Jennifer R. Brown
Jennifer R. Brown, MD, PhD

Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Dr Anne Quinquenel
Dr Anne Quinquenel, MD, PhD

Centre Hospitalier Universitaire de Reims
Université de Reims Champagne-Ardenne
Reims, France

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

This activity features insights from leading clinicians on the evidence that links the underlying mechanistic principles of Bruton tyrosine kinase inhibition with lessons arising from major clinical studies of first- and second-generation BTK agents in the chronic lymphocytic leukemia (CLL) setting.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Discuss the implications of mechanistic and selectivity difference among first- and second-generation BTK inhibitors in the context of CLL care
  • Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL
  • Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL and in patients unable to tolerate BTK inhibitor therapy
  • Manage the unique spectrum of toxicity associated with the use of BTK inhibitors in patients with CLL

Providership, Credit, and Support


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Creditâ„¢ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Faculty Disclosures

Chair & Presenter
Professor Florence Cymbalista, MD, PhD
Professor of Hematology
Department of Biological Hematology
Hopital Avicenne, AP-HP
University of Paris 13
Bobigny, France

Professor Florence Cymbalista, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche Ltd; Janssen Global Services, LLC; and Verastem, Inc.

Presenters
Jennifer R. Brown, MD, PhD
Director, CLL Center, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Jennifer R. Brown, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Acerta Pharma; AstraZeneca; BeiGene; Catapult Therapeutics; Dynamo Therapeutics; Juno/Celgene; Kite Pharma; Novartis Pharmaceuticals Corporation; Octapharma; Pharmacyclics; Sunesis Pharmaceuticals, Inc.; TG Therapeutics; and Verastem Oncology.
Grant/Research Support from Gilead Sciences, Inc.; Loxo Oncology; Sun Pharmaceuticals; and Verastem Oncology.
Honorarium from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support from Invectys for Safety Monitoring Committee.

Dr Anne Quinquenel, MD, PhD
Centre Hospitalier Universitaire de Reims
Université de Reims Champagne-Ardenne
Reims, France

Dr Anne Quinquenel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie and Janssen Pharmaceutica.
Speakers Bureau participant with AbbVie; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; and Janssen Pharmaceutica.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Shaina Rozell, MD, MPH

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.